Community News
-
The 10 key takeaways from CHS advocacy efforts to obtain access to emicizumab (Hemlibra)
by David Page, CHS National Director of Health Policy The Canadian Hemophilia Society (CHS), its chapters and members have expended great efforts to advocate for...
-
Hemlibra approved for all those with severe hemophilia A in Quebec – Access starts April 1
by David Page, CHS National Director of Health Policy March 1, 2022, Montréal – The Canadian Hemophilia Society (CHS) was informed yesterday by Héma-Québec that access...
-
Update on access to coagulation products for hemophilia A and B
by David Page, CHS National Director of Health Policy Access to a wide range of coagulation products is expanding in the provinces and territories served by...
-
David Page: Congratulations on 20 years of service!
Dear David, This is your 20th anniversary with the CHS and we would like to take this time to extend our deepest gratitude for all...
-
All About Mild Hemophilia
Mild hemophilia can be very serious and even life-threatening if injuries or bleeds are not treated promptly and adequately. The past few years, a lot...